Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease
Overview
Authors
Affiliations
Somatic genetic mutations involving the innate and inflammasome signaling are key drivers of the pathogenesis of myelodysplastic syndromes (MDS). Herein, we present a patient, who suffered from a long-standing refractory adult-onset autoinflammatory syndrome (AIS), previously interpreted as various distinct rheumatic disorders. Developing pancytopenia and particularly macrocytic anemia prompted the screening for a hematological malignancy, which led to the diagnosis of a -positive MDS. The impressive and continuously changing range of organ involvement, with remarkable refractoriness to anti-inflammatory treatment, exceeded the common autoinflammatory phenotype of MDS patients. This prompted us to suspect a recently discovered disease, characterized by somatic mutations of the gene: the VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome, which was ultimately confirmed by genetic testing. Reevaluation of previous bone marrow biopsies showed the presence of characteristic vacuoles in myeloid- and erythroid progenitor cells. Our case illustrates that the triad of an unresponsive multisystemic autoinflammatory disease, hematological abnormalities and vacuoles in myeloid- and erythroid progenitors in the bone marrow biopsy should prompt screening for the VEXAS syndrome.
Li X, Huang W, Yang X, Yang Q, Zheng Y, Huo Y Mol Med. 2024; 30(1):152.
PMID: 39289602 PMC: 11409618. DOI: 10.1186/s10020-024-00922-8.
Bixio R, Bindoli S, Morciano A, Padoan R, Aldegheri F, Mastropaolo F Intern Emerg Med. 2024; 19(8):2331-2345.
PMID: 39251478 PMC: 11582098. DOI: 10.1007/s11739-024-03763-9.
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.
Dias A, Groarke E, Hickstein D, Patel B Ann Hematol. 2024; 103(11):4427-4436.
PMID: 39168911 PMC: 11535077. DOI: 10.1007/s00277-024-05942-2.
Bellman P, Gonzalez-Lugo J, Shahzad M, Amin M, Khalid M, Suleman N Front Oncol. 2024; 14:1383730.
PMID: 38665946 PMC: 11043578. DOI: 10.3389/fonc.2024.1383730.
Padureanu V, Marinas C, Bobirca A, Padureanu R, Patrascu S, Dascalu A Cureus. 2024; 16(1):e53041.
PMID: 38410307 PMC: 10895688. DOI: 10.7759/cureus.53041.